The first of two late-stage trials of a new antibiotic being developed by Cubist Pharmaceuticals shows the drug works better than the existing standard of care, Levaquin, for treating complicated urinary tract infections.
November 25, 2013
The first of two late-stage trials of a new antibiotic being developed by Cubist Pharmaceuticals shows the drug works better than the existing standard of care, Levaquin, for treating complicated urinary tract infections.